Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 112

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 112
---
 the information and credentials to access, attend, participate or vote at the Special Meeting. Proxies appointing a third-party proxyholder must be deposited in accordance with the instructions set forth on the proxy card by no later than 10 a.m. (Montreal time) on January 14, 2026, or if the Annual Meeting is postponed or adjourned, by no later than 48 hours prior to the time of such postponed or adjourned meeting (excluding Saturdays, Sundays and holidays). We reserve the right to accept late proxies and to waive the proxy cut-off, withor without notice. Notice-And-Access The Company is not sending this Circular and Proxy Statement to Registered Shareholders or Beneficial Shareholders using “notice-and-access”under NI 54-101. Other Business We are not currently aware of any business to be acted upon at the Special Meeting other than the matters discussed in this Circular and Proxy Statement. If other matters do properly come before the Special Meeting, or at any adjournment or postponement of the Special Meeting, the persons named on the enclosed Form of Proxy gives will vote on them in accordance with their best judgment, pursuant to the discretionary authority conferred by the Form of Proxy with respect to such matters. 67

THE AGREEMENT

The Arrangement will be carried out pursuant to the Agreement and the Plan of Arrangement. The following is a summary of the principal terms
of the Agreement and Plan of Arrangement. This summary is qualified in its entirety by reference to the Agreement, which is attached to this Circular and Proxy Statement as Annex A and has been filed by the Company on its SEDAR+ profile at
www.sedarplus.ca, and to the Plan of Arrangement, which is attached to this Circular and Proxy Statement as Annex E.

Subject to the terms
and conditions of the Agreement, the Purchaser will acquire all of the issued and outstanding Common Shares in the capital of the Company. Upon completion of the Arrangement, each Shareholder of the Company (other than Dissenting Shareholders) will
receive, in exchange for each Common Share, the Consideration. The terms of the Agreement are the result of negotiations conducted between the Company and the Purchaser and their respective advisors.

Representations and Warranties

The
Agreement contains representations and warranties made by the Company to the Purchaser and the Parent and representations and warranties made by the Purchaser and the Parent to the Company. Those representations and warranties were made solely for
the purposes of the Agreement and